摘要
目的探讨贝伐珠单抗联合紫杉醇+铂类(TC)化疗方案对晚期卵巢癌患者肿瘤标志物水平及免疫功能的影响。方法队列研究。抽取2020年8月至2022年8月漯河市中心医院妇科收治的晚期卵巢癌患者94例,按照随机数字表法分为对照组与观察组,每组47例。观察组术后使用贝伐珠单抗联合TC化疗方案治疗,对照组术后仅使用TC化疗方案治疗。比较两组肿瘤标志物水平、免疫功能。结果治疗6个疗程后,两组人附睾分泌蛋白4、癌胚抗原、糖类抗原125水平均降低,且观察组低于对照组,差异有统计学意义(P<0.05);治疗6个疗程后,两组CD3^(+)、CD3^(+)CD4^(+)、CD4^(+)/CD8^(+)均升高,且观察组高于对照组,差异有统计学意义(P<0.05)。结论贝伐珠单抗联合TC化疗方案能提升晚期卵巢癌患者临床疗效,降低肿瘤标志物水平,改善免疫功能。
Objective To investigate the effect of bevacizumab combined with paclitaxel+platinum(TC)chemotherapy on patients with advanced ovarian cancer.Methods A total of 94 patients with advanced ovarian cancer treated in Department of Gynecology of Luohe Central Hospital from August 2020 to August 2022 were selected for the cohort study.And the selected patients were divided into a control group and an observation group by random number table method,with 47 cases in each group.The observation group was treated with bevacizumab combined with TC chemotherapy after surgery,and the control group was treated with TC chemotherapy alone after surgery.The levels of tumor markers and immune function of the two groups were compared.Results After 6 courses of treatment,the levels of human epididymis protein 4,carcinoembryonic antigen and carbohydrate antigen 125 in the two groups decreased,and the levels of the above indexes in the observation group were significantly lower than those in the control group(P<0.05).After 6 courses of treatment,levels of cluster of differentiation(CD)3^(+),CD3^(+)CD4^(+),and CD4^(+)/CD8^(+)in both groups increased,and the levels of the observation group were higher than those of the control group(P<0.05).Conclusions Bevacizumab combined with TC chemotherapy can improve the clinical efficacy,reduce tumor markers and improve immune function in patients with advanced ovarian cancer.
作者
李超华
Li Chaohua(Department of Gynecology,Luohe Central Hospital,Luohe 462000,China)
出处
《中国实用医刊》
2024年第6期102-104,共3页
Chinese Journal of Practical Medicine
关键词
卵巢癌
贝伐珠单抗
TC化疗方案
临床疗效
免疫功能
Ovarian neoplasms
Bevacizumab
Paclitaxel and platinum chemotherapy regimen
Clinical efficacy
Immunologic function
